MacroH2A1.2 reduces bone metastasis by attenuating the activity of lymphotoxin beta (LTβ) in prostate cancer and inhibiting secretion of lysyl oxidase (LOX) in breast cancer, thus exerting an anti-osteoclastogenic effect [89,141]. Here, LTB is linked to prostate cancer.